FibroPlant LNG IUS
Frameless LNG IUS
- User: Female
- Hormonal: Hormonal
-
Delivery type:
- Intrauterine
-
Intended Duration:
- Long-Acting
- Development Stage: Phase III
- Developer(s)/researcher(s): Contrel Research, Belgium, APCOR R&M, Belgium
Details
- API: Levonorgestrel
- Target: Progesterone Receptor
-
Mechanism of Action:
- Ovulation Inhibition
- Cervical Mucus Changes
- Endometrial Changes
- Inactive Materials: Ethylene Vinyl Acetate
- Regimen: 1 Insertion/3-5 Years
- MPT: Not Potential MPT
- Promising Attributes: Fibroplant is intended to maintain the positive side effects of approved hormonal IUDs while better suiting the needs of users with uterine cavities of varied sizes.
Product Status
Developer's corporate website does not list product. No publications after 2017.
History
Developed by Dr. Dirk Wildemeersch, FibroPlant was regularly evaluated in clinical contexts from 2000-2017.
Publications
doi: 10.1016/s0378-5122(00)00136-5
doi: 10.1080/13625180008500399
doi: 10.1080/13625180008500400
PMID: 11518454
PMID: 11848648
doi: 10.1016/s0301-2115(01)00555-3
doi: 10.1016/s0010-7824(02)00324-4
doi: 10.1016/s1472-6483(10)61919-0
doi: 10.1016/s0378-5122(03)00046-x
doi: 10.1016/j.contraception.2003.11.004
doi: 10.1016/j.maturitas.2003.07.002
doi: 10.1016/j.contraception.2004.02.005
doi: 10.1016/j.contraception.2004.02.004
doi: 10.1080/09513590500099156
doi: 10.1016/j.ejogrb.2005.10.029
doi: 10.1016/j.contraception.2006.12.023
doi: 10.1016/j.contraception.2008.09.007
doi: 10.3109/09513591003632308
doi: 10.2147/IJWH.S65462
doi: 10.2147/IJWH.S122579